The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Multimodal assessment of CMML with extramedullary involvement reveals RAS pathway activation
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study in which a multimodal assessment of chronic myelomonocytic leukemia (CMML) cases with extramedullary involvement was conducted. Dr Loghavi highlights that extramedullary disease in CMML was associated with RAS pathway activation, epithelial-mesenchymal transition, and diverse phenotypes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
